✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustry Why This Matters High cannabis taxes drive patients and consumers to unregulated illicit markets,...
RAAF veteran launches fundraising drive amid DVA framework changes | Cannabiz
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. Mental HealthPolicyResearchVeterans Why This Matters This article highlights emerging advocacy for cannabis-based treatments in veteran...
New Texas THC rules could ban smokable hemp by March 31 – Austin American-Statesman
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempTHCSafetyIndustry Why This Matters Clinicians need to understand these regulatory changes because patients currently using...
CED Digest: 392 Items — March 11, 2026
CED DigestMarch 11, 2026. 392 items curated for clinical relevance. Above Threshold #97Alabama Medical Cannabis Sales Gear for Spring 2026 Launch# Summary Alabama's medical cannabis program is preparing to begin retail sales...
Policy Watch: 16 Regulatory Updates — March 11, 2026
Policy WatchMarch 11, 2026. 16 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Clinical Summary # Clinical Summary The U.S. Drug Enforcement...
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Clinical Summary # Clinical Summary The Drug Enforcement Administration...
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters I don't see a summary provided...
Definition of Engaged in the Business as a Dealer in Firearms
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicyIndustry Clinical Summary I appreciate you providing the format guidelines,...
Schedules of Controlled Substances: Rescheduling of Marijuana
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicyResearchTHCSafety Clinical Summary The Drug Enforcement Administration's proposed rescheduling of...